Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Cash & Current Investments (2021 - 2025)

Historic Cash & Current Investments for Verrica Pharmaceuticals (VRCA) over the last 5 years, with Q3 2025 value amounting to $21.1 million.

  • Verrica Pharmaceuticals' Cash & Current Investments fell 826.09% to $21.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.1 million, marking a year-over-year decrease of 826.09%. This contributed to the annual value of $46.3 million for FY2024, which is 3338.46% down from last year.
  • Per Verrica Pharmaceuticals' latest filing, its Cash & Current Investments stood at $21.1 million for Q3 2025, which was down 826.09% from $15.4 million recorded in Q2 2025.
  • Verrica Pharmaceuticals' 5-year Cash & Current Investments high stood at $84.3 million for Q3 2023, and its period low was $15.4 million during Q2 2025.
  • Moreover, its 5-year median value for Cash & Current Investments was $34.3 million (2022), whereas its average is $39.6 million.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first surged by 15962.49% in 2023, then tumbled by 7271.91% in 2024.
  • Quarter analysis of 5 years shows Verrica Pharmaceuticals' Cash & Current Investments stood at $15.8 million in 2021, then surged by 117.58% to $34.3 million in 2022, then soared by 102.92% to $69.5 million in 2023, then tumbled by 33.38% to $46.3 million in 2024, then tumbled by 54.46% to $21.1 million in 2025.
  • Its last three reported values are $21.1 million in Q3 2025, $15.4 million for Q2 2025, and $29.6 million during Q1 2025.